
CNTB Stock Forecast & Price Target
CNTB Analyst Ratings
Bulls say
Connect Biopharma Holdings Ltd demonstrates a strong potential for growth due to the encouraging clinical efficacy results of its drug candidates, particularly with crossover patients witnessing 52-week improvements in IGA and EASI metrics, indicating significant therapeutic benefits. Additionally, the ongoing development of rademikibart via IV dosing could enhance its efficacy in acute settings, with clinical data anticipated around the end of 2025, further solidifying the company's innovative pipeline. The expectation of meaningful market uptake following these efficacy advancements and the critical timing associated with treatment underscores a positive outlook for the company's future performance in the competitive biopharmaceutical sector.
Bears say
Connect Biopharma Holdings Ltd faces significant challenges due to potential complications associated with dupilumab, including hyper-eosinophilia, which may deter its use in treatment settings and could limit the drug's marketability. The impending expiration of regulatory exclusivity and intellectual property protection for Dupixent, anticipated in 2029 and 2031, raises concerns about future revenue streams and the lack of new development efforts from Sanofi/Regeneron in light of high time and cost requirements. Additionally, expected resistance from payors regarding the use of dupilumab in acute settings due to insufficient clinical trial evidence further complicates its commercial viability.
This aggregate rating is based on analysts' research of Connect Biopharma Holdings and is not a guaranteed prediction by Public.com or investment advice.
CNTB Analyst Forecast & Price Prediction
Start investing in CNTB
Order type
Buy in
Order amount
Est. shares
0 shares